We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]
Boston Scientific (BSX) stock declined 47% over the last 12 months to trade near $57. Despite total revenues growing 17.4% to $20.6 billion and net income margins improving to 17.3%, the P/E multiple contracted by 70%. The selloff was triggered by a Q4 2025 GAAP EPS miss and a significant full-year 2026 organic growth guidance cut. The company's management lowered the target from a 10 to 11% range down to 6.5 to 8.0%, attributing the reset to greater-than-expected market share loss in the Electr
Everyone is still glued to Tesla (NASDAQ:TSLA) because a Q1 earnings beat, the robotaxi pitch, and the Optimus humanoid tease have convinced retail traders the autonomy story finally pays off this year. The Tesla Trade Is Crowded and Priced for a Miracle Tesla carries a P/E of 406 and a free cash flow yield of ... Forget Tesla. The Robotics Company Actually Shipping Revenue Has a $22 Billion Backlog and Nobody Is Talking About It
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Recent performance context for Intuitive Surgical Intuitive Surgical (ISRG) has been under pressure recently, with the stock down about 10% over the past month and about 15% over the past 3 months. This has prompted investors to reassess expectations. See our latest analysis for Intuitive Surgical. Beyond the recent pullback, the stock has also declined about 25% based on the year to date share price return, even though the 3 year and 5 year total shareholder returns remain positive. If you...
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics. That flywheel is the moat. The three companies owning the installed bases to build it are Intuitive Surgical (NASDAQ: ISRG), Medtronic (NYSE: MDT), and ... Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays
Intuitive Surgical is in its own bear market, which has historically been a good time for aggressive growth investors to buy.
ISRG's da Vinci 5 is driving stronger utilization and procedure growth, but can higher throughput and after-hours surgeries sustain momentum?
Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]
ISRG nears a key support level after a 23.7% YTD drop, but strong da Vinci 5 adoption and procedure growth may fuel a rebound.
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
The heavy selling pressure might have exhausted for Intuitive Surgical (ISRG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Many investors understandably have doubts about the company right now.
Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Wondering if Intuitive Surgical at around US$453 per share is still worth your attention, or if the stock price already reflects most of the opportunity? The stock has been relatively flat over the past week with a 0.9% decline and is roughly unchanged over 30 days. Year to date it is down 19.3%, the 1 year return sits at a 15.7% decline, and the 3 year and 5 year returns are 49.4% and 65.8% respectively. Recent share price moves come as investors continue to assess the company's position in...
Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio. Chairman, Chief Executive Officer a
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
R. Jeffrey Bailly: Thank you, Ron, and thank you to everyone joining the call. UFP had a strong second quarter. Revenue from our two largest customers, Intuitive Surgical and Stryker, grew 10% and 567%, respectively.
Why Intuitive Surgical stock is drawing attention now Intuitive Surgical (ISRG) is back in focus after a choppy stretch for the stock, prompting investors to reassess how its current share price lines up with recent returns and the scale of its surgical robotics business. See our latest analysis for Intuitive Surgical. At a share price of US$457.78, Intuitive Surgical has seen a 1-day share price return close to flat, a 7-day share price return of a 2.8% decline, and a year-to-date share...
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said: Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit […]
Intuitive Surgical makes surgical robots, but that's not how it makes most of its money.
Intuitive Surgical (NASDAQ:ISRG) stockholders voted to approve all four proposals presented at the company’s 2026 Annual Meeting of Stockholders, which was held virtually, according to meeting remarks led by Gary Loeb, executive vice president and chief legal and compliance officer. Annual meeting
Intuitive Surgical faces mixed international trends as China pressure and Japan delays cloud otherwise strong OUS growth outlook.
Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure growth and expansion of the da Vinci and Ion platforms. CEO David Rosa pointed to a 17% increase in total procedures, including “broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care.” The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding uptake
Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.